Old Web
English
Sign In
Acemap
>
authorDetail
>
A. de la Peña
A. de la Peña
Eli Lilly and Company
Medicine
Internal medicine
Osteoarthritis
Physical therapy
Placebo
3
Papers
38
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial
2018
Osteoarthritis and Cartilage
Yan Jin
Claire Smith
David Monteith
R. Brown
A. Camporeale
Terry A. McNearney
Mark A. Deeg
Eyas Raddad
N. Xiao
A. de la Peña
Alan J. Kivitz
Thomas J. Schnitzer
Show All
Source
Cite
Save
Citations (19)
Differential effects of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide and metformin on pancreatic β‐cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes
2016
Diabetes, Obesity and Metabolism
Andrea Mari
S. Del Prato
Bernhard Ludvik
Zvonko Milicevic
A. de la Peña
L. Shurzinske
Chrisanthi A. Karanikas
V. Pechtner
Show All
Source
Cite
Save
Citations (9)
LY2951742, a monoclonal antibody against CGRP, failed to reduce signs and symptoms of knee osteoarthritis
2016
Osteoarthritis and Cartilage
Yan Jin
Claire Smith
David Monteith
R. Brown
A. Camporeale
Terry A. McNearney
Mark A. Deeg
Eyas Raddad
A. de la Peña
Alan J. Kivitz
Thomas J. Schnitzer
Show All
Source
Cite
Save
Citations (10)
1